Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 31 - Medicinal preparations containing organic active ingredients
Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
07/2012
07/31/2012CA2626700C Pharmaceutical compositions containing erythrina mulungu derivatives, processes for their production and uses thereof
07/31/2012CA2597699C Bisphosphonates for treating endometriosis
07/31/2012CA2575620C A method for preparing penicillin g procaine
07/31/2012CA2569088C Pyrrolobenzimidazolones and their use as antiproliferative agents
07/31/2012CA2565708C 5,6-diphenyl-1,2,4-triazinic dimeric derivatives and the use thereof in the form of sun-protective agents
07/31/2012CA2565629C Process for preparing atazanavir bisulfate and novel forms
07/31/2012CA2565599C Substituted 2-quinolyl-oxazoles useful as pde4 inhibitors
07/31/2012CA2553877C Compounds useful for the synthesis of s- and r-omeprazole and a process for their preparation
07/31/2012CA2541849C Liquid preparation containing tobramycin
07/31/2012CA2539909C 1,1,1-trifluoro-4-phenyl-4-methyl-2-(1h-pyrrolo(2,3-c) pyridin-2-ylmethyl) pentan-2-ol derivatives and related compounds as glucocorticoid ligands for the treatment of inflammatory diseases and diabetes
07/31/2012CA2528323C 2-hydroxymethyl-3,4,5-trihydroxy-1-benzilpiperidine derivatives as inhibitors of glucosylceramide
07/31/2012CA2528322C 2-hydroxymethyl-3,4,5-trihydroxy-1-(4-pentlyoxybenzyl) piperidine as glucosylceramide synthase (gcs)
07/31/2012CA2518328C Method for preparing transcription factors and use
07/31/2012CA2517491C Injectable liquid formulation of paracetamol
07/31/2012CA2515505C Inhibitor for perioperative blood sugar elevation
07/31/2012CA2506464C Therapeutic agent for glaucoma comprising rho kinase inhibitor and .beta.-blocker
07/31/2012CA2503445C Methylene urea derivatives as raf-kinase inhibitors
07/31/2012CA2499128C Indazoles, benzothiazoles, and benzoisothiazoles, and preparation and uses thereof
07/31/2012CA2494089C Polysaccharide of echinacea angustifolia
07/31/2012CA2489965C Pharmaceutical compositions for the treatment of diseases related to neurotrophines
07/31/2012CA2475214C Streptomyces avermitilis gene directing the ratio of b2:b1 avermectins
07/31/2012CA2465375C 2-aryl-propionic acids and pharmaceutical compositions containing them
07/31/2012CA2458471C Prostaglandin analogs as chloride channel opener
07/31/2012CA2449999C Compounds and methods for the treatment or prevention of flavivirus infections
07/31/2012CA2433857C Inositol phosphoglycan derivatives and their medical uses
07/31/2012CA2411919C Immunization of dairy cattle with chimeric gapc protein against streptococcus infection
07/31/2012CA2404688C Nuclear factor .kappa.b inducing factor
07/31/2012CA2358958C Soy depigmenting and skin care compositions
07/31/2012CA2348624C Adenovirus-mediated gene therapy
07/31/2012CA2223402C Methods of inhibiting phagocytosis
07/26/2012WO2012100262A1 Therapeutic method using anti - ctgf antibody
07/26/2012WO2012100238A2 Compounds and methods for enhancing hair growth
07/26/2012WO2012100229A2 Compositions and methods for cardiovascular disease
07/26/2012WO2012100228A2 Methods and compositions for treating kidney disorders
07/26/2012WO2012100223A1 Synthetic lethal targeting of glucose transport
07/26/2012WO2012100208A1 Modified release compositions of epalrestat or a derivative thereof and methods for using the same
07/26/2012WO2012100142A2 Treatments for retinal disorders
07/26/2012WO2012100135A1 Picolinamide inhibitors of kinases
07/26/2012WO2012100109A2 Therapeutic eye drop comprising doxycycline and a stabilizer
07/26/2012WO2012100073A1 Selective calcium channel antagonists
07/26/2012WO2012100045A2 Methods of predicting response to jnk inhibitor therapy
07/26/2012WO2012100017A2 Antiretroviral cyclonucleoside compositions and methods and articles of manufacture therewith
07/26/2012WO2012099980A2 Equine nutritional supplement
07/26/2012WO2012099962A2 Pharmaceutical compositions and methods for making and using them
07/26/2012WO2012099952A2 Benzofuro[3,2-c] pyridines and related analogs as serotonin sub-type 6 (5-ht6) modulators for the treatment of obesity, metabolic syndrome, cognition and schizophrenia
07/26/2012WO2012099942A2 Methods and compositions for treating metabolic syndrome
07/26/2012WO2012099930A2 Flavonol compositions
07/26/2012WO2012099916A1 Quinazolinone inhibitors of dynein
07/26/2012WO2012099915A1 Thiazolidine derivatives and their therapeutic use
07/26/2012WO2012099871A1 Modulation of lrch4 activity and therapeutic application thereof
07/26/2012WO2012099836A1 Treatment of cognitive dysfunction in schizophrenia
07/26/2012WO2012099807A1 Olefin containing nuclear transport modulators and uses thereof
07/26/2012WO2012099785A2 Modulators of tlr3/dsrna complex and uses thereof
07/26/2012WO2012099770A2 Diazeniumdiolate derivatives
07/26/2012WO2012099717A1 Leukotrienes and asthma exacerbation risk
07/26/2012WO2012099703A1 Wound healing device and method
07/26/2012WO2012099630A1 Compositions and methods for treating or preventing a retrovirus infection
07/26/2012WO2012099581A1 Dihydrofuropyrimidine compounds
07/26/2012WO2012099557A2 Fatty acid inhibitors
07/26/2012WO2012099479A1 Injectable compositions for mastitis comprising an nsaid and an antibiotic in a non-aqueous solvent
07/26/2012WO2012099477A1 Biosurface engineering
07/26/2012WO2012099454A1 Curcumin compounds and their preparations thereof
07/26/2012WO2012099453A1 Pyrrolothiazole containing curcumin compounds
07/26/2012WO2012099452A1 Curcumin compounds with superior structural stability and processes for their preparation
07/26/2012WO2012099451A1 Curcumin compounds containing indolizine and their preparations thereof
07/26/2012WO2012099449A2 Novel use of flavone-based compound
07/26/2012WO2012099381A2 Preparation method of intermediate of sitagliptin
07/26/2012WO2012099375A2 P47phox or p67phox-targeting therapeutic agent for stress disorders, and method for screening for same
07/26/2012WO2012099285A1 Nano ceramic bone cement using animal bones and preparation method thereof
07/26/2012WO2012099260A1 Orally dispersible tablet
07/26/2012WO2012099247A1 Skin whitening agent
07/26/2012WO2012099238A1 Composition for promoting lipolysis
07/26/2012WO2012099200A1 Pyrazole derivative
07/26/2012WO2012099142A1 Bromfenac aqueous liquid composition having preservative efficiency
07/26/2012WO2012099139A1 FERRIC CITRATE CONTAINING SUBSTANTIALLY NO β-OXIDIZED IRON HYDROXIDE
07/26/2012WO2012099129A1 Compound having anti-cancer activity
07/26/2012WO2012099082A1 Branched-chain amino acid-containing jelly
07/26/2012WO2012098692A1 Composition for inhibiting target gene expression
07/26/2012WO2012098557A1 Pegylated gemcitabine derivative and process for preparing the same
07/26/2012WO2012098505A1 2-methoxy-pyridin-4-yl derivatives
07/26/2012WO2012098501A1 Febuxostat co-crystals
07/26/2012WO2012098499A1 Solid molecular dispersion
07/26/2012WO2012098495A1 Pharmaceutical composition that includes revamilast and a beta-2 agonist
07/26/2012WO2012098465A1 Pvrl4 (nectin 4) is a receptor for measles virus
07/26/2012WO2012098416A1 Diarylacetylene hydrazide containing tyrosine kinase inhibitors
07/26/2012WO2012098400A1 Piperazine derivatives as cav2.2 calcium channel blockers
07/26/2012WO2012098387A1 6, 7-ring-fused triazolo [4, 3 - b] pyridazine derivatives as pim inhibitors
07/26/2012WO2012098342A1 (r)-1,2-propanediol for use as a solvent in therapeutic cooling agent compositions
07/26/2012WO2012098282A1 Additives for animal food
07/26/2012WO2012098237A1 Compounds with super-aspirin effects
07/26/2012WO2012098234A1 Biologically active nucleotide molecules for selectively killing off cells, use thereof, and application kit
07/26/2012WO2012098217A1 Fused dihydrofurans as gpr119 modulators for the treatment of diabetes, obesity and related disorders
07/26/2012WO2012098213A1 Fused aminodihydrothiazine derivatives useful as bace inhibitors
07/26/2012WO2012098208A1 Use of stathmin as a biomarker of drug response to furazanobenzimidazoles
07/26/2012WO2012098207A1 Use of bubr1 as a biomarker of drug response to furazanobenzimidazoles
07/26/2012WO2012098203A1 Use of glu-tubulin as a biomarker of drug response to furazanobenzimidazoles
07/26/2012WO2012098172A2 N-arylaminomethylene benzothiophenones for treatment of cardiovascular disease
07/26/2012WO2012098143A1 Use of inhibitors of atp-sensitive potassium channels for the treatment of hearing loss
07/26/2012WO2012098134A1 Monoterpene derivatives of chalcone or dihydrochalcone and their use as depigmenting agents
07/26/2012WO2012098132A1 Novel 4-amino-n-hydroxy-benzamides as hdac inhibitors for the treatment of cancer
1 ... 1108 1109 1110 1111 1112 1113 1114 1115 1116 1117 1118 1119 1120 1121 1122 1123 1124 1125 1126 1127 1128 ... 7860